Revolution Medicines Adds RM-055 And First Line Data To RAS Story

Simply Wall St.04-26 05:14

Revolution Medicines (NasdaqGS:RVMD) reported preclinical data for RM-055, a new class of catalytic RAS(ON) inhibitors that convert oncogenic RAS to an inactive state in multiple cancer models. The ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2630802492?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-26 05:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630802492","market":"hk","top_or_hot":-1,"title":"Revolution Medicines Adds RM-055 And First Line Data To RAS Story","media":"Simply Wall St.","content":"<div>\n<p>Revolution Medicines (NasdaqGS:RVMD) reported preclinical data for RM-055, a new class of catalytic RAS(ON) inhibitors that convert oncogenic RAS to an inactive state in multiple cancer models. The ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-adds-rm-055-and-first-line-data-to-ras\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revolution Medicines Adds RM-055 And First Line Data To RAS Story</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevolution Medicines Adds RM-055 And First Line Data To RAS Story\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-26 05:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-adds-rm-055-and-first-line-data-to-ras><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Revolution Medicines (NasdaqGS:RVMD) reported preclinical data for RM-055, a new class of catalytic RAS(ON) inhibitors that convert oncogenic RAS to an inactive state in multiple cancer models. The ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-adds-rm-055-and-first-line-data-to-ras\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1854103824.USD","symbol_name":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-adds-rm-055-and-first-line-data-to-ras","article_id":"2630802492","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-adds-rm-055-and-first-line-data-to-ras","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2630802492","pubTimestamp":1777151654,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Revolution Medicines (NasdaqGS:RVMD) reported preclinical data for RM-055, a new class of catalytic RAS(ON) inhibitors that convert oncogenic RAS to an inactive state in multiple cancer models.\nThe company also shared updated first line clinical data for daraxonrasib in untreated metastatic pancreatic cancer, supporting further Phase 3 evaluation.\nThese announcements expand beyond prior late stage updates that focused on second line pancreatic cancer data and related financings.\n\nFor...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","BK4585":"ETF&股票定投概念","BK4141":"半导体产品","IE00BD6J9T35.USD":"NEUBERGER BERMAN NEXT GENERATION MOBILITY \"A\" (USD) ACC","BK4139":"生物科技","LU1861214812.USD":"Blackrock Future of Transport A2 USD","IE00BZ199S13.USD":"BNY MELLON MOBILITY INNOVATION \"B\" (USD) ACC","BK4166":"消费信贷","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","LU1861219969.SGD":"Blackrock Future of Transport A2 SGD-H","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","BK4605":"半导体精选","BK4588":"碎股","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU1861215975.USD":"贝莱德新一代科技基金 A2","ON":"安森美半导体","LU1548497426.USD":"安联环球人工智能AT Acc","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU2360107325.USD":"BGF FUTURE OF TRANSPORT \"A4\" (USD) INC","LU1861220033.SGD":"Blackrock Next Generation Technology A2 SGD-H","LU0124384867.USD":"贝莱德新能源基金A2","LU2298322129.HKD":"BGF SUSTAINABLE ENERGY \"A2\" (HKDHDG) ACC","RM":"Regional Management Corp","LU0724618433.USD":"BGF NEW ENERGY \"A4\" (USD) INC","RVMD":"Revolution Medicines, Inc.","LU1978683503.SGD":"Blackrock Sustainable Energy A2 SGD-H","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","BK4512":"苹果概念"},"translate_title":"Revolution Medicines将RM-055和一线数据添加到RAS故事中","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RM":1.5,"ON":1,"RVMD":1.5},"content_text":"Revolution Medicines (NasdaqGS:RVMD) reported preclinical data for RM-055, a new class of catalytic RAS(ON) inhibitors that convert oncogenic RAS to an inactive state in multiple cancer models. The company also shared updated first line clinical data for daraxonrasib in untreated metastatic pancreatic cancer, supporting further Phase 3 evaluation. These announcements expand beyond prior late stage updates that focused on second line pancreatic cancer data and related financings.  For investors tracking Revolution Medicines at a share price of $135.3, the stock has had a sharp move over the past year, with a 249.0% return and a very large gain over 3 years. Year to date, the stock is up 71.2%, although it has seen a 9.0% decline over the past week, which may reflect investors reassessing near term expectations after a 43.5% gain over 30 days. These RM-055 preclinical results and first line daraxonrasib data provide additional context for how broadly the RAS focused pipeline could reach across tumor settings and treatment lines. As Phase 3 enrollment advances and the RM-055 program matures, upcoming readouts and trial design updates are likely to influence how the market views NasdaqGS:RVMD’s longer term opportunity set in oncology. Stay updated on the most important news stories for Revolution Medicines by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Revolution Medicines. NasdaqGS:RVMD 1-Year Stock Price Chart See which insiders are buying and buying and selling Revolution Medicines following this latest news. For existing and potential shareholders, the RM-055 and first line daraxonrasib updates add another layer to an already crowded RAS story. RM-055 sits earlier in the pipeline, but the idea of a catalytic inhibitor that can convert oncogenic RAS back to its inactive state and address resistance could matter for how long current and future RAS(ON) drugs stay relevant in the treatment sequence. At the same time, fresh first line daraxonrasib data in untreated metastatic pancreatic cancer connects directly to the ongoing RASolute 303 trial and builds on the previously treated RASolute 302 results, which already met all primary and key secondary endpoints. Together, this gives investors more clinical detail to weigh against a share price that has moved sharply, and a capital structure that now includes a US$1.5b equity raise and US$500m of convertible notes. The combination of maturing late stage assets, earlier stage pipeline optionality and recent financings helps explain why trading has been active as different investors reassess risk, reward and time horizon. AdvertisementHow This Fits Into The Revolution Medicines Narrative  The new RM-055 resistance focused data and first line daraxonrasib experience both align with the narrative that a multi drug RAS(ON) portfolio can address high unmet need tumors across several lines of therapy, potentially extending treatment duration per patient. The same concentration in RAS targeted programs highlighted in the narrative also means that setbacks in RM-055 or first line pancreatic trials would affect more than one part of the story at once, which could challenge expectations built around multiple successful Phase 3 programs. The specific concept of a catalytic RAS(ON) inhibitor aimed at resistance, along with how investors react to the large recent equity and convertible raises, may not be fully captured in existing community narratives that focus more on RASolute 302 and headline expense guidance.  Knowing what a company is worth starts with understanding its story.\nCheck out one of the top narratives in the Simply Wall St Community for Revolution Medicines to help decide what it is worth to you. The Risks and Rewards Investors Should Consider  ⚠️ Revolution Medicines currently reports no revenue and is guiding for US$1.6b to US$1.7b of GAAP operating expenses in 2026, so the company is relying on trial success and future approvals to justify high cash use. ⚠️ All core assets target the RAS pathway, so competition from other RAS and immuno oncology drugs from players such as Amgen, Bristol Myers Squibb and AstraZeneca, as well as potential resistance mechanisms, could limit long run market share. 🎁 RASolute 302 showed a large overall survival benefit versus chemotherapy in metastatic pancreatic cancer, supported by FDA Breakthrough Therapy and Orphan Drug designations, which could support a differentiated position if approved. 🎁 Zoldonrasib’s early lung cancer data with a 52% objective response rate and a 93% disease control rate in KRAS G12D NSCLC, together with RM-055’s preclinical resistance story, suggest a pipeline that extends beyond a single tumor setting and gives multiple shots on goal within RAS driven cancers.  What To Watch Going Forward Investors will want to follow how detailed first line daraxonrasib data in metastatic pancreatic cancer feed into the RASolute 303 program, including safety, durability of response and any subgroup outcomes that could matter for future labeling and uptake. For RM-055, the key questions are how quickly the program moves toward human studies and whether early clinical signals eventually confirm its preclinical resistance profile. It is also worth watching how the market digests the recent equity and convertible offerings over time, including any updates on cash runway, additional Phase 3 commitments and potential partnerships with larger oncology players. To ensure you are always in the loop on how the latest news impacts the investment narrative for Revolution Medicines, head to the\ncommunity page for Revolution Medicines to never miss an update on the top community narratives.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2630802492","isCrawlerRequest":true}